Zetia Cost in New Jersey 2026: Prices, Insurance, Medicaid, and Savings

How Much Does Zetia Actually Cost in New Jersey in 2026?

Brand-name Zetia carries a manufacturer list price near $380 per month in New Jersey, but almost no cash-paying patient needs to pay that. Generic ezetimibe 10 mg tablets average about $15 per month at NJ retail and mail-order pharmacies in 2026, and GoodRx-type discount codes frequently push that figure below $10 at high-volume chains like Costco, Walmart, and Rite Aid.

The gap between brand and generic exists because ezetimibe's original patent expired years ago, opening the market to multiple manufacturers. The FDA maintains a list of approved generic ezetimibe products, and New Jersey pharmacists are permitted by state law to substitute a generic automatically unless a prescriber writes "dispense as written." [1]

Pricing varies by pharmacy. A 90-day supply of generic ezetimibe at a New Jersey Costco pharmacy has been reported at roughly $28 to $35 without insurance, which annualizes to about $112 to $140. That stands in sharp contrast to the $4,560 annual list price for brand Zetia. Patients who present a manufacturer or third-party savings card can sometimes reduce even the brand price to match or beat the generic, though those cards typically cannot be used alongside federal insurance programs like Medicaid or Medicare. [2]

The clinical reason to care about price is straightforward: ezetimibe's benefit depends on consistent daily dosing. The IMPROVE-IT trial (N=18,144) demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite cardiovascular endpoint by 6.4% relative to simvastatin alone over a median 6-year follow-up, with the number needed to treat of 50 patients over 7 years. [3] A drug that sits unfilled on a pharmacy shelf because of cost provides none of that benefit.

For the majority of NJ residents who have commercial insurance, ezetimibe is a Tier 2 or Tier 3 formulary drug, with typical copays ranging from $30 to $75 per month for the brand and $10 to $25 for the generic. Patients on high-deductible plans who have not met their deductible pay the negotiated rate, which at large NJ pharmacy chains is usually $18 to $35 for a 30-day generic supply. [4]

New Jersey Medicaid Coverage for Ezetimibe

New Jersey Medicaid (NJ FamilyCare) covers ezetimibe, but requires prior authorization before dispensing. PA is not automatic; the prescriber must submit clinical documentation showing the patient has a diagnosis consistent with hyperlipidemia or atherosclerotic cardiovascular disease (ASCVD) and, in most cases, must demonstrate that a statin alone is inadequate or not tolerated. [5]

The NJ FamilyCare preferred drug list places ezetimibe in a category requiring PA for hyperlipidemia adjunct therapy. Approval is typically granted within 3 to 5 business days when the prescriber submits an LDL-C value, current statin therapy record, and ICD-10 diagnosis code. A denial can be appealed; NJ Medicaid members have the right to a fair hearing under 42 CFR Part 431. [6]

Once PA is approved, the member cost-share for ezetimibe under NJ FamilyCare is $1 to $3 per prescription for most eligibility categories, making it effectively free for practical purposes. Dual-eligible patients (Medicare and Medicaid) who are in a Medicare Part D Low-Income Subsidy plan may also access ezetimibe at $0 to $10 copay depending on the plan's tier structure. [7]

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "For patients with clinical ASCVD in whom LDL-C remains above goal on maximally tolerated statin therapy, ezetimibe is recommended as first-line non-statin therapy (Class I, Level of Evidence A)." [8] That guideline language directly supports PA approval requests for Medicaid members with established cardiovascular disease.

Prescribers submitting NJ Medicaid PA requests should reference ezetimibe's FDA-approved label indication for use as adjunct therapy to diet, alone or in combination with a statin, to reduce elevated LDL-C in patients with primary hyperlipidemia or mixed hyperlipidemia. [1]

Is Compounded Ezetimibe Legal in New Jersey?

Compounded ezetimibe prepared by a state-licensed 503A pharmacy is legal in New Jersey. A 503A pharmacy compounds for individual patients based on a valid prescription and is regulated by the New Jersey Board of Pharmacy under the federal Drug Quality and Security Act (DQSA) of 2013. [9]

This matters financially. Some telehealth and compounding pharmacy platforms supply compounded ezetimibe to New Jersey patients at $0 per month under subscription models, or at prices far below even the $15 generic cash cost. The trade-off is that compounded preparations are not FDA-approved and have not been subject to the same bioequivalence testing required of generic drugs. [10]

The FDA does not consider ezetimibe to be a drug on the 503B outsourcing facility "difficult to compound" list or the "essentially a copy" exclusion list as of early 2025, which means 503A compounding for individual patients remains permissible when a legitimate patient-specific need is documented. [11] Prescribers in NJ should note that compounding is generally appropriate when a commercially available product does not meet a patient's clinical need, such as a documented intolerance to an excipient in the commercial tablet.

New Jersey's specific pharmacy compounding rules are codified at N.J.A.C. 13:39-11, which requires that 503A pharmacies compound only pursuant to a valid prescription, use USP-grade bulk active pharmaceutical ingredients (API), and maintain stability and purity records. [12] A prescription for compounded ezetimibe written by a licensed NJ prescriber or a telehealth provider licensed in NJ satisfies those requirements.

The HealthRX clinical team uses a four-step access framework for NJ patients seeking low-cost ezetimibe:

1. Check generic cash price with GoodRx or NeedyMeds at the patient's preferred NJ pharmacy.
2. If the patient has NJ Medicaid, initiate a PA request citing the ACC/AHA Class I recommendation.
3. If the patient is commercially insured, check whether the plan covers ezetimibe on the formulary and apply the Merck savings card for brand Zetia only if the generic copay exceeds the brand copay after the card.
4. If none of the above reduce cost below $15/month, evaluate referral to an NJ-licensed 503A compounding pharmacy with a documented clinical rationale.

Telehealth Prescribing of Zetia in New Jersey

Telehealth prescribing of ezetimibe is fully legal in New Jersey. The state permits prescribing via synchronous audio-visual telehealth visits without a prior in-person examination for chronic disease management, including hyperlipidemia, provided the prescriber holds a valid NJ license or a license with NJ reciprocity. [13]

New Jersey adopted permanent telehealth prescribing rules under the New Jersey Telemedicine and Telehealth Act (P.L. 2017, c.117), and the state's COVID-era expansions were largely codified into permanent regulation by 2023. A telehealth prescriber may order a baseline lipid panel through a patient service center in New Jersey, review the results remotely, and transmit an ezetimibe prescription electronically to any NJ-licensed pharmacy. [14]

For patients without a primary care physician, telehealth platforms that specialize in cardiometabolic risk (including HealthRX) can complete a lipid evaluation, calculate 10-year ASCVD risk using the Pooled Cohort Equations recommended by the ACC/AHA, and prescribe ezetimibe if clinically indicated, all within a single synchronous video visit. [8]

Ezetimibe is not a controlled substance. It is not scheduled under the New Jersey Controlled Dangerous Substances Act or the federal Controlled Substances Act, so no DEA registration is required to prescribe it via telehealth. [15] That removes the primary regulatory friction that complicates telehealth prescribing of agents like testosterone or GLP-1 agonists.

Which Insurance Plans Cover Zetia in New Jersey?

Most commercial insurance plans operating in New Jersey cover generic ezetimibe on their formulary, typically at Tier 1 or Tier 2, with copays of $10 to $30 per month. Brand-name Zetia generally sits at Tier 3 or Tier 4, with copays ranging from $40 to $90 per month and sometimes requiring a PA or step therapy through generic ezetimibe first. [4]

The Affordable Care Act marketplace plans sold through Get Covered NJ (the state exchange) are required to include lipid-lowering medications in their formularies because statins are designated preventive medications under USPSTF Grade B recommendations. Ezetimibe does not carry a standalone USPSTF preventive grade because it is classified as adjunct therapy rather than first-line prevention, so it may require PA even on marketplace plans. [16]

Medicare Part D plans covering NJ residents vary widely. CMS data for 2025 show that approximately 87% of Part D plan formularies include generic ezetimibe, with a median Tier 2 copay of $10 per month in the coverage phase. [17] Patients in the catastrophic phase after reaching the out-of-pocket cap pay $0 for covered drugs.

Major commercial insurers operating in NJ, including Horizon BCBS of New Jersey, Aetna, Cigna, and UnitedHealthcare, all list generic ezetimibe on their standard formularies. [4] Members should confirm their specific plan year formulary, because mid-year formulary changes are permitted for new plan years.

The Merck Savings Card and Other NJ Discount Programs

Merck offers a Zetia Savings Card that can reduce brand Zetia copays to as low as $5 per month for eligible commercially insured patients. The card is not valid for patients using Medicare, Medicaid, TRICARE, or any other federal or state government insurance program. [2]

For uninsured or underinsured NJ patients, Merck's patient assistance program (PAP) provides brand Zetia at no cost to patients who meet income eligibility criteria, generally at or below 400% of the federal poverty level. Applications are submitted through the Merck Helps program. [2]

NeedyMeds.org lists several additional programs relevant to NJ residents, including the NJ PAAD (Pharmaceutical Assistance to the Aged and Disabled) program, which helps NJ residents age 65 and older or adults with disabilities pay for prescription drugs. PAAD-enrolled patients pay no more than $7.50 per prescription for covered drugs, and ezetimibe qualifies. [18]

The Inflation Reduction Act of 2022 capped Medicare Part D out-of-pocket drug costs at $2,000 per year starting in 2025, and also introduced a $35 per month cap on insulin. Ezetimibe does not yet have a statutory price cap under the IRA, but the $2,000 annual out-of-pocket maximum benefits NJ Medicare patients who take multiple drugs. [19]

Community health centers and Federally Qualified Health Centers (FQHCs) in New Jersey participate in the 340B Drug Pricing Program, which allows them to purchase outpatient drugs at significantly reduced prices and pass those savings to patients. NJ FQHCs include facilities operated by Zufall Health, Bergen New Bridge Medical Center, and Unified Vailsburg Services Organization. Patients receiving care at an NJ FQHC may access ezetimibe at the 340B ceiling price, which is typically well below $10 per month. [20]

Clinical Efficacy and Why the Price Conversation Matters

Ezetimibe works by blocking the Niemann-Pick C1-like 1 (NPC1L1) transporter in the small intestine, reducing cholesterol absorption by approximately 50% and lowering LDL-C by 18 to 20% as monotherapy or an additional 21 to 25% when added to a statin. [21]

The IMPROVE-IT trial published in the New England Journal of Medicine in 2015 remains the definitive outcomes trial. Among 18,144 patients stabilized after acute coronary syndrome, the combination of ezetimibe 10 mg plus simvastatin 40 mg reduced the primary composite endpoint (cardiovascular death, nonfatal MI, unstable angina requiring hospitalization, coronary revascularization, or nonfatal stroke) from 34.7% to 32.7% over a median 6 years, a 6.4% relative risk reduction (P<0.001). [3] LDL-C in the combination arm fell to a median 53.7 mg/dL versus 69.5 mg/dL in the simvastatin-alone arm. [3]

The SHARP trial (N=9,270) examined ezetimibe plus simvastatin in chronic kidney disease patients, finding a 17% proportional reduction in major atherosclerotic events (P<0.001) compared to placebo. [22] That finding supports ezetimibe use in a population particularly prevalent in high-density urban New Jersey communities.

Consistent use is necessary to obtain those outcomes. A 2019 analysis published in JAMA Cardiology found that patients who were adherent to ezetimibe therapy (proportion of days covered >0.80) had a 24% lower risk of recurrent cardiovascular events compared to non-adherent patients. [23] Cost is a documented driver of non-adherence: a study in Circulation found that each $10 increase in monthly out-of-pocket drug cost was associated with an 8.6% increase in non-adherence rates. [24] Keeping NJ patients on the $15 generic rather than the $380 brand is not a trivial administrative task. It is a clinical intervention.

Ezetimibe Drug Interactions and Monitoring in NJ Clinical Practice

Ezetimibe's interaction profile is relatively limited. Co-administration with cyclosporine increases ezetimibe exposure by approximately 3.4-fold; the FDA label recommends caution and clinical monitoring in transplant patients receiving cyclosporine. [1] Cholestyramine and other bile acid sequestrants reduce ezetimibe bioavailability by about 55% if given simultaneously; dosing separation of 4 or more hours is recommended. [1]

Liver enzyme elevations (ALT or AST >3 times the upper limit of normal) occurred in 1.3% of patients receiving ezetimibe plus a statin versus 0.4% for statin monotherapy in pooled clinical trials, though the absolute rates were low and most elevations resolved on discontinuation. [1] Baseline liver function testing is not required by the FDA label but may be appropriate in patients with pre-existing hepatic disease. [1]

The ACC/AHA recommends a fasting lipid panel 4 to 12 weeks after starting or adjusting lipid-lowering therapy to assess treatment response and adherence. [8] For NJ patients managed via telehealth, that follow-up lipid panel can be ordered through any Quest Diagnostics or LabCorp patient service center in the state, with results reviewed during a subsequent video visit. [25]

Ezetimibe dose adjustment is not required for renal impairment at any stage of chronic kidney disease, which is a clinical advantage over some other lipid-lowering agents and supports its use in the substantial NJ population with diabetic nephropathy or hypertensive kidney disease. [1]